{"organizations": [], "uuid": "f4f9b7cc2a508a84f9e8e898672189f534f76416", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abeona-therapeutics-provides-clini/brief-abeona-therapeutics-provides-clinical-update-on-mps-iiia-gene-therapy-trial-idUSASC0A2XQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.994, "site_type": "news", "published": "2018-05-18T21:36:00.000+03:00", "replies_count": 0, "uuid": "f4f9b7cc2a508a84f9e8e898672189f534f76416"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abeona-therapeutics-provides-clini/brief-abeona-therapeutics-provides-clinical-update-on-mps-iiia-gene-therapy-trial-idUSASC0A2XQ", "ord_in_thread": 0, "title": "BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abeona therapeutics inc", "sentiment": "negative"}, {"name": "biophysical", "sentiment": "none"}, {"name": "abeona therapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18 (Reuters) - Abeona Therapeutics Inc:\n* ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING\n* ABEONA THERAPEUTICS- ABO-102 18-MONTH EFFICACY & SAFETY DATA CONTINUE TO DEMONSTRATE TIME- & DOSE-DEPENDENT REDUCTIONS IN UNDERLYING DISEASE PATHOLOGY\n* ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN\n* ABEONA THERAPEUTICS INC - ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-18T21:36:00.000+03:00", "crawled": "2018-05-19T15:31:44.008+03:00", "highlightTitle": ""}